Effect of CDK4/6 Inhibitor Palbociclib and Metformin in Ovarian Cancer: Cyclin D as a new Target?

被引：0
|
作者：
Tsibulak, I [1 ]
Hagenbuchner, J. [2 ]
Ausserlechner, M. [2 ]
Wieser, V [1 ]
Marth, C. [1 ]
Zeimet, A. G. [1 ]
Fiegl, H. [1 ]
机构：
[1] Med Univ Innsbruck, Univ Klin Gynakol & Geburtshilfe, Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Kinder & Jugendheilkunde, Innsbruck, Austria
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1055/s-0039-3403403
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
19
引用
收藏
页码：436 / 436
页数：1
相关论文
共 50 条
  • [1] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [2] Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer
    Chen, Fengquan
    Liu, Chunxi
    Zhang, Jian
    Xu, Wenfang
    Zhang, Yingjie
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (09) : 1241 - 1251
  • [3] Clarithromycin Interactions with Palbociclib (CDK4/6 Inhibitor)
    Hu, Xiuqiong
    Yang, Wei
    Liu, Lanjie
    Qin, Hua
    LATIN AMERICAN JOURNAL OF PHARMACY, 2021, 40 (07): : 1698 - 1707
  • [4] Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
    Min, Ahrum
    Kim, Jung Eun
    Kim, Yu-Jin
    Lim, Jee Min
    Kim, Seongyeong
    Kim, Jin Won
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Oh, Do-Youn
    Bang, Yung-Jue
    Im, Seock-Ah
    CANCER LETTERS, 2018, 430 : 123 - 132
  • [5] Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
    van Aken, Evert S. M.
    Beeker, Aart
    Houtenbos, Ilse
    Pos, Floris J.
    Linn, Sabine C.
    Elkhuizen, Paula H. M.
    de Jong, Monique C.
    CANCER REPORTS, 2022, 5 (02)
  • [6] Palbociclib, a CDK4/6 inhibitor, suppresses proliferation of triple negative breast cancer
    Min, Ahrum
    Kim, Yu Jin
    Hang, Hyemin
    Lim, Jee Min
    Kim, Seongyeong
    Kim, So Hyeon
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [7] TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML
    Uras, I.
    Valent, P.
    Sexl, V.
    HAEMATOLOGICA, 2017, 102 : 207 - 208
  • [8] Factors that limit delivery of Cdk4/6 inhibitor palbociclib to GBM
    Parrish, K.
    Pokorny, J.
    Mittapalli, R.
    Bakken, K.
    Sarkaria, J.
    Elmquist, W.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 86 - 86
  • [9] Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
    Guillaume, Zoe
    Medioni, Jacques
    Lillo-Lelouet, Agnes
    Marret, Gregoire
    Oudard, Stephane
    Simonaggio, Audrey
    CLINICAL BREAST CANCER, 2020, 20 (02) : E192 - E195
  • [10] CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
    Zhang, Kai
    Hong, Ruoxi
    Kaping, Lee
    Xu, Fei
    Xia, Wen
    Qin, Ge
    Zheng, Qiufan
    Lu, Qianyi
    Zhai, Qinglian
    Shi, Yanxia
    Yuan, Zhongyu
    Deng, Wuguo
    Chen, Miao
    Wang, Shusen
    CANCER LETTERS, 2019, 447 : 130 - 140
12345